RxDoctor Payments Data

Eduardo Nevarez Carrilo, MD

Family Medicine · Melbourne, FLNPI 1386785624

Payments from drug & device makers

$692in general payments, 2019–2025

Across 31 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$263
  • Boehringer Ingelheim$104
  • Lilly USA, LLC$94
  • Novo Nordisk$70
  • E.r. Squibb & Sons, L.L.C.$50
  • Amgen$24
  • plus $88 from 5 others

What the payments were for

  • Food & beverage$692100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$692 in reported general payments places this provider in the 55th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$125,976
Medicare patients
409
Services billed
2,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide79$94,465
JardianceEmpagliflozin95$90,822
EliquisApixaban49$50,782
XareltoRivaroxaban36$40,711
TradjentaLinagliptin31$25,518
EntrestoSacubitril/Valsartan25$16,514
MyrbetriqMirabegron14$11,540
Breo ElliptaFluticasone/Vilanterol17$10,073
Atorvastatin Calcium581$8,331
Levothyroxine Sodium363$6,621
Losartan Potassium402$5,741
Amlodipine Besylate577$4,834
Dexlansoprazole DrDexlansoprazole21$4,329
Albuterol Sulfate HfaAlbuterol Sulfate96$4,215
Omeprazole269$3,953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$104$116,340126 claims
Novo NordiskOzempic$70$94,46579 claims
Johnson & JohnsonXarelto$13$40,71136 claims
NovartisEntresto$19$16,51425 claims
AbbVieSynthroid$21$1,89939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →